Find clinical trials for Lymphoma in Detroit, MI

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Detroit, MI, USA:

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary object...

Active, not recruiting

B Cell Lymphoma

Mantle Cell Lymphoma

Drug: Ibrutinib

Drug: Palbociclib

Phase 2

Alliance Foundation Trials

Ypsilanti, Michigan, United States and 8 other locations

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling

Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

Drug: ARV-393

Phase 1

Arvinas

Detroit, Michigan, United States and 13 other locations

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Enrolling

T-cell Lymphoma

Cutaneous T-cell Lymphoma

Drug: Fenretinide

Phase 1

SciTech Development

Detroit, Michigan, United States and 8 other locations

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting

Non-Hodgkin Lymphoma

Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis

Detroit, Michigan, United States and 66 other locations

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...

Active, not recruiting

Non Hodgkin Lymphoma

Drug: acalabrutinib

Drug: rituximab (IV)

Phase 1, Phase 2